Who owns AGIOS PHARMACEUTICALS, INC. (AGIO)? Elite investor 13F holders
2 tracked elite investors reported holding AGIOS PHARMACEUTICALS, INC as of 2026-06-30, including D.E. Shaw, Tudor Investment. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.
2 tracked investors currently reported holding · Latest report period: 2026-06-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product is also used for the treatment…
Reported holders and securities, including exits (up to 20)
| Investor | Security | Instrument | Report period | Filed | Value | Quantity | Units | Change | Source |
|---|---|---|---|---|---|---|---|---|---|
| D.E. Shaw | AGIOS PHARMACEUTICALS INC | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 115300956.00 USD | 3107005.000000 | Shares | add | Original filing |
| Tudor Investment | AGIOS PHARMACEUTICALS INC | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 2441059.00 USD | 65779.000000 | Shares | add | Original filing |
Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.
This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.